Abstract
Background: Lutetium-177 (177Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic (GEP) NETs. However, radiation can cause transient inflammation/swelling of tumors, which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described. We investigated the potential for intestinal ischemia in177Lu-DOTATATE-treated patients. Methods: Clinical records were reviewed of patients with midgut NETs treated with177Lu-DOTATATE at the Moffitt Cancer Center between April 2018 and December 2022 and at The Ohio State University between December 2017 and October 2020. Results: Among the cases reviewed, we identified three patients who developed bowel ischemia/perforation shortly after their initial treatment with177Lu-DOTATATE. All patients had metastatic small bowel NET with prominent mesenteric mass encasing/obstructing the mesenteric vessels and preexisting symptoms of postprandial abdominal pain. Conclusion: Acute bowel ischemia may be a rare complication of PRRT in patients with mesenteric arterial or venous obstruction from mesenteric metastasis.
| Original language | English |
|---|---|
| Article number | e250033 |
| Journal | Endocrine Oncology |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2025 |
Keywords
- PRRT
- bowel ischemia
- mesenteric lesions
- small bowel NET
Fingerprint
Dive into the research topics of 'Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with177Lu-DOTATATE'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver